Experienced in Upper Tract Urothelial Carcinoma (UTUC)

Dr. Alexander N. Starodub

Hematology Oncology | Hematology | Oncology
Christ Hospital Medical Specialists Ii, LLC
2139 Auburn Ave, 
Cincinnati, OH 
Accepting New Patients
Experienced in Upper Tract Urothelial Carcinoma (UTUC)
Christ Hospital Medical Specialists Ii, LLC
2139 Auburn Ave, 
Cincinnati, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Alexander Starodub is a Hematologist Oncology specialist and a Hematologist in Cincinnati, Ohio. Dr. Starodub is rated as an Experienced provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). His top areas of expertise are Colorectal Cancer, Pancreatic Cancer, Familial Colorectal Cancer, Pleuropulmonary Blastoma, and Bone Marrow Aspiration. Dr. Starodub is currently accepting new patients.

His clinical research consists of co-authoring 21 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in OH
Hospital Affiliations
Riverside Regional Medical Center
Christ Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Health
  • HMO
  • PPO
Medical Mutual
  • HMO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

CHRIST HOSPITAL MEDICAL SPECIALISTS II, LLC
2139 Auburn Ave, Cincinnati, OH 45219
Other Locations
CHRIST HOSPITAL MEDICAL SPECIALISTS II, LLC
1955 Dixie Hwy, Suite G, Fort Wright, KY 41011

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 16, 2025
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
Enrollment Status: Active_not_recruiting
Publish Date: April 18, 2025
Intervention Type: Procedure, Biological, Drug, Radiation
Study Drugs: Docetaxel, Nab-Paclitaxel, Paclitaxel, Pertuzumab, Trastuzumab, Trastuzumab Emtansine
Study Phase: Phase 2
A Phase 1b, Open-Label, Dose-Escalation, Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
A Phase 1b, Open-Label, Dose-Escalation, Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: August 09, 2024
Intervention Type: Drug
Study Drugs: SM08502, Abiraterone, Prednisone, Docetaxel, FOLFIRI Protocol, Panitumumab
Study Phase: Phase 1
An Open-Label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Pre- and Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
An Open-Label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Pre- and Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Enrollment Status: Active_not_recruiting
Publish Date: April 18, 2024
Intervention Type: Drug
Study Drugs: Lasofoxifene, Fulvestrant
Study Phase: Phase 2
A Phase I/II Study of Once or Twice Weekly IMMU-130 (hMN-14-SN38, Antibody-Drug Conjugate) in Patients With Colorectal Cancer
A Phase I/II Study of Once or Twice Weekly IMMU-130 (hMN-14-SN38, Antibody-Drug Conjugate) in Patients With Colorectal Cancer
Enrollment Status: Terminated
Publish Date: January 24, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
An Open Label, Escalating Multiple Dose Study to Evaluate the Safety, Toxicity, Pharmacokinetics, and Preliminary Activity of BTX-1188 in Subjects With Advanced Malignancies
An Open Label, Escalating Multiple Dose Study to Evaluate the Safety, Toxicity, Pharmacokinetics, and Preliminary Activity of BTX-1188 in Subjects With Advanced Malignancies
Enrollment Status: Terminated
Publish Date: September 18, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Dose Escalation With Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMV564 Alone and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
A Phase 1 Dose Escalation With Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMV564 Alone and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Enrollment Status: Unknown
Publish Date: October 19, 2021
Intervention Type: Biological
Study Phase: Phase 1
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancer
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancer
Enrollment Status: Completed
Publish Date: August 12, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: June 02, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase l/ll Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-CD27 Antibody (Varlilumab) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
A Phase l/ll Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-CD27 Antibody (Varlilumab) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
Enrollment Status: Completed
Publish Date: December 09, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase I A/B Study of the Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors
A Phase I A/B Study of the Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: February 07, 2019
Intervention Type: Drug
Study Phase: Phase 1
An Intensive QT/QTc Study to Investigate the Effects of Rovalpituzumab Tesirine on Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer
An Intensive QT/QTc Study to Investigate the Effects of Rovalpituzumab Tesirine on Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: September 24, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 11 Less Clinical Trials

21 Total Publications

Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors.
Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors.
Journal: Journal for immunotherapy of cancer
Published: June 09, 2022
Similar Doctors
Advanced in Upper Tract Urothelial Carcinoma (UTUC)
Dr. William G. Danneman
Oncology | Hematology Oncology | Hematology
Advanced in Upper Tract Urothelial Carcinoma (UTUC)
Dr. William G. Danneman
Oncology | Hematology Oncology | Hematology
1 Medical Village Dr, 
Edgewood, KY 
 (8.0 miles away)
859-301-4000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

William Danneman is an Oncologist and a Hematologist Oncology provider in Edgewood, Kentucky. Dr. Danneman is rated as an Advanced provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). His top areas of expertise are Upper Tract Urothelial Carcinoma (UTUC), Iron Deficiency Anemia, Follicular Lymphoma, Childhood Iron Deficiency Anemia, and Bone Marrow Aspiration. Dr. Danneman is currently accepting new patients.

Advanced in Upper Tract Urothelial Carcinoma (UTUC)
Dr. Brian Mannion
Hematology | Oncology
Advanced in Upper Tract Urothelial Carcinoma (UTUC)
Dr. Brian Mannion
Hematology | Oncology

Christ Hospital Medical Specialists Ii, LLC

1955 Dixie Hwy, Suite G, 
Fort Wright, KY 
 (5.0 miles away)
859-331-3304
Languages Spoken:
English
See accepted insurances

Brian Mannion is a Hematologist and an Oncologist in Fort Wright, Kentucky. Dr. Mannion is rated as a Distinguished provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). His top areas of expertise are Pleuropulmonary Blastoma, Paget Disease of the Breast, Lung Cancer, and Angiosarcoma.

Advanced in Upper Tract Urothelial Carcinoma (UTUC)
Dr. Nkeiruka E. Okoye
Hematology Oncology | Hematology | Oncology
Advanced in Upper Tract Urothelial Carcinoma (UTUC)
Dr. Nkeiruka E. Okoye
Hematology Oncology | Hematology | Oncology

Dayton Physicians LLC

501 Atrium Dr, Suite 100, 
Middletown, OH 
 (28.3 miles away)
937-293-1622
Languages Spoken:
English, Yoruba
See accepted insurances
Accepting New Patients
Offers Telehealth

Nkeiruka Okoye is a Hematologist Oncology specialist and a Hematologist in Middletown, Ohio. Dr. Okoye is rated as an Advanced provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). Her top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Familial Colorectal Cancer, Colorectal Cancer, and Bone Marrow Aspiration. Dr. Okoye is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Starodub's expertise for a condition
ConditionClose
    View All 25 Advanced Conditions
    View All 144 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile